🩸 Breakthrough in Multiple Myeloma Treatment! 🩺

🩸 Breakthrough in Multiple Myeloma Treatment! 🩺

LANCET

🔬Targeting GPRC5D with CAR-T Cells shows immense potential in treating relapsed or refractory multiple myeloma patients.
Multiple myeloma, a malignant disease characterized by clonal plasma cell proliferation in the bone marrow, has remained incurable despite substantial progress in treatment methods such as systemic chemotherapy, radiation therapy, and hematopoietic stem cell transplantation (HSCT). However, CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has demonstrated activity in treating relapsed or refractory multiple myeloma. Nonetheless, the escape of BCMA-low or BCMA-negative myeloma cells has led to treatment resistance and relapse, highlighting the need to explore new targets.

💪In February 2023, a groundbreaking study titled “GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-center, single-arm, phase 1 trial” was published in The Lancet Haematology. The study aimed to evaluate the activity and safety of G-protein-coupled receptor class 5 member D (GPRC5D) CAR-T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma.

🌈Promising Treatment Response with OriCAR-017 Infusion
All ten patients (100%) demonstrated an overall response, with 6 patients (60%) achieving a complete response and 4 patients (40%) showing very good partial responses. The patients with complete responses met stringent complete response criteria, and all patients achieved minimal residual disease (MRD) negativity by day 28. Serum M-protein concentrations gradually decreased, and patients’ clinical responses improved over time. The median time to the best response was 3.1 months, while the median time to a complete response or better was 4.1 months.

☀️Among the 5 patients who relapsed after BCMA CAR-T cell therapy, 2 patients achieved a stringent complete response, and 3 patients showed very good partial responses. Four patients had extramedullary disease at enrollment, with the largest tumor volume measuring 70 cm³. PET-CT scans revealed complete resolution of extramedullary lesions in three patients, while the extramedullary disease in one patient continued to shrink. Furthermore, no severe adverse events or treatment-related deaths were reported.

🌱Favorable Survival Outcomes after OriCAR-017 Infusion
⏰The median follow-up time for all patients was 238 days, with two patients progressing after achieving stringent complete remission. One patient experienced GPRC5D-positive relapse, with GPRC5D expression in malignant plasma cells increasing from 34.5% at baseline to 35.8% at relapse. The other patient experienced GPRC5D-negative relapse, with GPRC5D expression in malignant plasma cells decreasing from 86.8% at baseline to 6.9% at relapse. The remaining eight patients in ongoing remission were all negative for minimal residual disease, and no deaths occurred. The median progression-free survival time was not reached, but the estimated progression-free survival rate for all patients at nine months was 87.5%.

🧬Durable CAR-T Cell Persistence
✨CAR-T cell expansion was detected in all patients after infusion, with a median time to maximum CAR-T cell expansion (Cmax) of 10.0 days and a median Cmax of 7930 copies/μl. CAR-T cells exhibited favorable persistence in the body, with CAR-T cells still detectable in 90% of patients at one month, seven patients at three months, and four patients at six months.

🌟 The study results demonstrate that targeting GPRC5D with CAR-T cells in treating relapsed or refractory multiple myeloma patients is safe and shows promising activity. The observed targeted and off-target toxicities associated with GPRC5D were manageable, indicating the potential of GPRC5D as an effective immunotherapeutic target for multiple myeloma. These findings provide a foundation for subsequent phase 2 studies to further validate the efficacy and safety of targeting GPRC5D CAR-T cells in multiple myeloma.🦾

We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
doctor.huang@globecancer.com
WhatsApp+8613717959070

🔬 Stay tuned for more updates on this groundbreaking research! Together, we can conquer multiple myeloma!

#MultipleMyelomaResearch #CARTTherapy #GPRC5D #MedicalBreakthrough #cart #multiplemyeloma #chinesecart #cartcell #carttherapy #LANCET #Haematology #CARTCell

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy

👑🍋Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy👑🍋

Multiple Myeloma

 

💪Meet John, a resilient man from New Zealand who has been battling multiple myeloma, a relentless form of cancer. Severe bone pain has confined him to bed for an extended period, disrupting his daily life. However, a glimmer of hope emerged when he sought treatment at Renji Hospital’s Hematology Department in Shanghai, China.

🍒Renji Hospital’s medical team, led by Professor Hou Jian, specializes in CAR-T cell therapy, a revolutionary approach to target cancer cells with precision. John’s journey began eleven years ago when he was diagnosed with multiple myeloma. Despite undergoing numerous chemotherapy sessions and two autologous stem cell transplants, his condition deteriorated rapidly over the past year.

🍈Intense back pain rendered him unable to stand or walk, forcing him into prolonged bed rest and heavy reliance on pain medication. Further assessments revealed widespread extramedullary plasmacytomas in his bones and throat, along with complex chromosomal abnormalities, indicating a grim prognosis.

🍓Having exhausted conventional treatments, John explored alternative options and learned about Renji Hospital’s expertise in CAR-T cell therapy for refractory multiple myeloma. In 2016, Professor Hou Jian’s team initiated clinical trials utilizing CAR-T cell therapy, accumulating significant experience in treating relapsed and refractory cases.

🍇Upon evaluation, John’s medical team identified substantial tumor burden and compromised bone marrow function due to extensive chemotherapy. Despite the challenges, Professor Hou Jian’s team tailored a personalized treatment plan, opting for dual CAR-T therapy targeting CD19 and BCMA antigens.

🥑John has since returned to New Zealand and maintains regular contact with his medical team at Renji Hospital. Ongoing monitoring and follow-ups ensure his progress is closely tracked. “John is gradually reclaiming his daily life. Recently, he even shared photos of hiking and fishing adventures with us,” Professor Hou Jian shared.

🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

 

#CARTtherapy #MultipleMyeloma #PrecisionTreatment #RenjiHospital #HopeInHealthcare #CART #cancer #cancertreatment #medicaltourism #tuomor #cartcell #CARTtherapy

1 year ago CAR-T

Unveiling Hope: Chinese CAR-T Cell Therapy Illuminating New Paths in Liver Cancer Treatment!

2020, over 19.3 million people were diagnosed with cancer worldwide, leading to almost 10 million fatalities. In China alone, the number of new cancer patients reached a staggering 4.57 million, accounting for 23.7% globally. Liver cancer, among the most prevalent malignant tumors in China, witnessed 410,000 new cases and 380,000 deaths, making up 45.3% and 47.1% of the global total, respectively [1]. However, since the 21st century began, significant strides have been made in liver cancer treatments, particularly in medication and localized therapies. Surgical procedures are no longer the sole option for long-term survival among liver cancer patients.

Immunotherapy has emerged as one of the most promising techniques for treating liver cancer, especially with advancements in tumor molecular biology. In 2013, “Science” magazine categorized immunotherapy as the fourth major cancer treatment, following surgery, chemotherapy, and radiation therapy, with cell therapy becoming a focal point of basic and clinical research in recent years.

In May 2020, Professor Zhai Bo’s team from Shanghai Jiao Tong University School of Medicine’s Renji Hospital, in collaboration with Shanghai Sci-Tech Biotechnology’s team led by Li Zonghai, published groundbreaking preliminary clinical research data on CAR-T cell therapy targeting the GPC3 gene for hepatocellular carcinoma in the “Clinical Cancer Research” journal. This breakthrough study brought unprecedented hope for CAR-T cell therapy in liver cancer treatment.

Even more inspiring, their publication in the “Cancer Communications” journal showcased follow-up results of two late-stage liver cancer patients who achieved long-term tumor-free survival after receiving CAR-T cell combined with local therapy [2]. These findings shed new light on the treatment prospects for liver cancer patients.

However, despite the potential therapeutic effects of liver cancer CAR-T cell therapy, it faces challenges and obstacles. Liver cancer’s heterogeneity, tumor microenvironment, and the safety of cell therapy remain crucial issues to address.

Presently, revolutionary changes are underway in the treatment models and concepts for liver cancer. However, integrating CAR-T cell therapy into actual liver cancer treatment requires further scientific exploration and clinical research. Researchers emphasize that only through comprehensive utilization of CAR-T cells in conjunction with other treatment modalities can its therapeutic potential be fully realized.

Professor Zhai Bo’s team is currently conducting various fundamental and clinical studies aimed at exploring additional possibilities for CAR-T cell therapy in solid tumors. These studies include phase I clinical research on EpCAM CAR-T cell combined with ablative therapy for gastrointestinal tumors, phase II clinical research on Claudin18.2 CAR-T cell therapy for gastrointestinal tumors, studies on the mechanism and prevention of OTOT toxicity, among others. These endeavors will provide more experimental data and support for the application of CAR-T cells in the treatment of solid tumors.

In conclusion, liver cancer CAR-T cell therapy signifies a significant breakthrough in the field of liver cancer treatment, offering new hope for patients. Despite the challenges to overcome, the outlook for this therapy is promising and holds the potential to bring a blessing to more patients in the future.

[References]

Zhaibo, Lizonghai etc.

“Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials.” 《Clinical Cancer Research》, 2020.

“Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.” 《Cancer Communications》, 2023.

 

#HealthTech#CancerResearch #Immunotherapy #CARTcell #LiverCancer #MedicalBreakthrough #ClinicalTrials #ScienceNews #HealthcareInnovation #ResearchBreakthrough #MedicalScience #CancerTherapy #CancerAwareness #InnovativeMedicine #ImmunotherapyTreatment #ScienceUpdates #HealthcareTechnology #BiomedicalResearch #ClinicalInnovation #CancerTreatment #MedicalAdvancements #ImmunologyResearch #HealthcareIndustry #ProfessionalHealthcare